Overview
flowchart TD
Iron["Iron"] -->|"causes"| Phospholipid_Peroxidation["Phospholipid Peroxidation"]
Iron["Iron"] -->|"involved in"| Neurotransmitter_Synthesis["Neurotransmitter Synthesis"]
Iron["Iron"] -->|"involved in"| Mitochondrial_Metabolism["Mitochondrial Metabolism"]
iron["iron"] -->|"drives"| ferroptosis["ferroptosis"]
iron["iron"] -->|"binds"| FTH1["FTH1"]
Iron["Iron"] -->|"causes"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"mediates"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"involved in"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"involved in"| Myelination["Myelination"]
Iron["Iron"] -->|"causes"| Oxidative_Stress["Oxidative Stress"]
iron["iron"] -->|"mediates"| oxidative_stress["oxidative stress"]
iron["iron"] -->|"binds"| FTMT["FTMT"]
Iron["Iron"] -->|"associated with"| Microglia["Microglia"]
Iron["Iron"] -->|"associated with"| Ferroptosis["Ferroptosis"]
style IRON fill:#4fc3f7,stroke:#333,color:#000
Executive Summary
Target: Brain iron accumulation in neurodegenerative diseases
Approach: Use iron chelators (deferiprone, deferasirox, deferoxamine) to reduce brain iron levels and prevent iron-mediated oxidative damage
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Progressive Supranuclear Palsy, Corticobasal Syndrome
Score: 74/100
Mechanism of Action
Iron Accumulation in Neurodegeneration
...Overview
Mermaid diagram (expand to render)
Executive Summary
Target: Brain iron accumulation in neurodegenerative diseases
Approach: Use iron chelators (deferiprone, deferasirox, deferoxamine) to reduce brain iron levels and prevent iron-mediated oxidative damage
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Progressive Supranuclear Palsy, Corticobasal Syndrome
Score: 74/100
Mechanism of Action
Iron Accumulation in Neurodegeneration
Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression[@martin2020]. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA[@halliwell1992].
Key mechanisms include:
- Oxidative stress: Iron catalyzes the formation of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), leading to lipid peroxidation and mitochondrial dysfunction[@jomova2010]
- Protein aggregation: Iron promotes the aggregation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) in AD and [alpha-synuclein](/proteins/alpha-synuclein) in PD[@bansal2019]
- Neuroinflammation: Iron-activated microglia release pro-inflammatory cytokines, exacerbating neuronal death[@zhang2022]
- [Ferroptosis](/entities/ferroptosis): Iron-dependent programmed cell death has been implicated in neurodegeneration[@stockwell2017]
The FAIR-PARK Hypothesis
The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata[@dexter1991]. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity[@wang2021].
Chelating Agents
Deferiprone
- Mechanism: Bidentate oral chelator that passes [BBB](/entities/blood-brain-barrier) and can mobilize brain iron
- Clinical evidence: FAIRPARK study showed reduced iron in substantia nigra and slower disease progression in PSP and PD[@devos2018]
- Dosing: 20-40 mg/kg/day oral, divided twice daily
- Monitoring: Weekly neutrophil count due to agranulocytosis risk
Deferasirox
- Mechanism: Tridentate oral chelator with better BBB penetration than deferoxamine[@guldberg2013]
- Clinical trials: Phase II trials in PD and PSP (FAIRPARK-II)
- Dosing: 20-40 mg/kg/day oral
Deferoxamine
- Mechanism: Hexadentate chelator that binds Fe³⁺ with high affinity
- Administration: Subcutaneous or intravenous infusion
- Challenges: Poor BBB penetration, rapid metabolism
Scoring (10-Dimension Rubric)
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 6 | Iron chelation is established in other contexts; repurposing for neurodegeneration |
| Mechanistic Rationale | 9 | Strong evidence for iron's role in oxidative stress and protein aggregation |
| Root-Cause Coverage | 8 | Addresses iron accumulation, a upstream pathological driver |
| Delivery Feasibility | 6 | Some agents cross BBB; deferiprone best brain penetration |
| Safety Plausibility | 6 | Known safety profile but agranulocytosis risk (deferiprone) |
| Combinability | 8 | Works with antioxidants, CoQ10, neuroprotective agents |
| Biomarker Availability | 9 | MRI iron quantification (R2*, SWI), oxidative stress biomarkers |
| De-risking Path | 8 | FAIRPARK trials provide proof-of-concept; existing approved agents |
| Multi-disease Potential | 9 | AD, PD, PSP, CBS, ALS - broad applicability |
| Patient Impact | 7 | Addresses fundamental aging-related pathology |
Total: 74/100
Clinical Evidence
Parkinson's Disease
- FAIRPARK trial: Demonstrated reduced iron in substantia nigra and slower disease progression with deferiprone[@devos2022]
- Combination therapy: Iron chelation combined with dopaminergic medications shows synergistic effects[@weinreb2013]
Progressive Supranuclear Palsy
- FAIR-PARK-II trial: Reduced brain iron levels on MRI with slower decline on PSP Rating Scale[@moreau2022]
Alzheimer's Disease
- Deferoxamine trial (1988): Crapper McLachlan et al. showed reduced rate of cognitive decline[@crapper1988]
- Deferasirox trials: Phase II studies showed reduced CSF biomarkers of oxidative stress
Combination Therapy Opportunities
Synergistic Targets
+ Coenzyme Q10: Addresses mitochondrial dysfunction synergistically[@spindler2019]
+ N-acetylcysteine: Supports glutathione replenishment
+ Antioxidants: Rutin, quercetin, and other flavonoids
+ Ferrostatin-1 analogs: Direct ferroptosis inhibition complementary to chelationPreclinical Combination Data
- Deferiprone + CoQ10: Synergistic neuroprotection in PD models
- Deferasirox + N-acetylcysteine: Enhanced antioxidant effects
Development Pathway
Phase 1: Patient Selection
- Identify patients with elevated brain iron on MRI (R2*, SWI)
- Stratify by disease stage - early intervention most effective
- Select iron-accumulating disease subtypes (PD, PSP, CBS)
Phase 2: Combination Optimization
- Test deferiprone + CoQ10 in prodromal PD
- Evaluate deferasirox + vitamin D combination
- Optimize dosing to minimize agranulocytosis risk
Phase 3: Biomarker Validation
- Validate MRI iron quantification as prognostic biomarker
- Establish CSF ferritin as treatment response marker
- Develop point-of-care iron monitoring
Risks and Mitigations
| Risk | Mitigation |
|------|------------|
| Agranulocytosis (deferiprone) | Weekly CBC monitoring; dose titration |
| Iron deficiency | Monitor serum ferritin; maintain adequate levels |
| BBB penetration variability | Use brain-penetrant agents; optimize delivery |
| Limited efficacy in advanced disease | Early intervention; patient selection |
Competitive Landscape
Iron chelation for neurodegeneration is being pursued by:
- FAIRPARK consortium: Deferiprone in PD/PSP (Phase II)
- Neuroderm: Novel brain-penetrant iron chelators (preclinical)
- Various academic groups: Repurposing existing chelators
Cross-Links
Diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Ferroptosis](/mechanisms/ferroptosis)
Mechanisms
- [Iron Metabolism](/mechanisms/iron-metabolism)
- [Oxidative Stress](/mechanisms/oxidative-stress)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Ferroptosis](/mechanisms/ferroptosis)
Proteins & Genes
- [Ferritin](/proteins/ferritin)
- [Transferrin](/proteins/transferrin)
- [DMT1](/genes/dmt1)
- [FPN](/genes/slc40a1)
Cell Types
- [Neurons](/cell-types/neurons)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Astrocytes](/cell-types/astrocytes)
Treatments
- [Iron Chelation Therapy](/therapeutics/iron-chelation-therapy)
- [Neuroprotective Agents](/therapeutics/neuroprotective-agents)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Actionable Next Steps
Research Gap: Detailed next steps to be developed based on current evidence
Expert Consultation: Seek input from domain specialists
Evidence Review: Conduct systematic review of available dataImplementation Roadmap
Phase 1: Discovery & Validation (Year 1)
| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Target validation | Months 1-3 | MRI iron quantification protocol standardization, patient stratification biomarkers | Research team |
| Lead compound selection | Months 4-6 | Compare deferiprone, deferasirox, novel chelators for brain penetration | Medicinal chemistry |
| In vitro proof-of-concept | Months 6-12 | iPSC neuron testing, dose-response, iron mobilization assays | Preclinical team |
Budget: $2-5M
Phase 2: Preclinical Development (Year 2)
| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Animal efficacy | Months 13-18 | MPTP/6-OHDA PD models, APP/PS1 AD models | In vivo pharmacology |
| GLP toxicology | Months 15-21 | 28-day, 90-day studies with focus on hematological safety | Toxicology |
| Formulation development | Months 18-24 | Brain-penetrant chelator optimization, combination formulation | Pharmaceutical development |
Budget: $8-15M
Phase 3: Clinical Development (Years 3-5)
| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Phase 1 | Months 24-30 | First-in-human safety, PK in neurodegeneration patients | Clinical operations |
| Phase 2a | Months 30-42 | Dose-finding, MRI iron reduction endpoints | Clinical development |
| Phase 2b | Months 42-60 | Registrational study in PSP/PD | Clinical development |
Budget: $30-50M (phased)
Key Academic Centers
- University of Lille, France (FAIRPARK consortium)
- Parkinson's UK Cambridge Brain Bank
- Mayo Clinic Rochester
- Columbia University Movement Disorders
Potential Partners
- Novartis (deferasirox franchise)
- Chiesi (rare disease pipeline)
- Takeda (neurology division)
- GTx (novel iron chelators)
- Biohaven (neuroprotection platform)
References
[Martin WR, et al, Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32855230/)
[Halliwell B, Reactive oxygen species and the central nervous system (1992)](https://pubmed.ncbi.nlm.nih.gov/1402908/)
[Jomova K, et al, Metals, oxidative stress and neurodegenerative disorders (2010)](https://doi.org/10.1007/s11010-010-0563-x)
[Bansal S, et al, Iron accelerates amyloid-beta aggregation and enhances oxidative stress in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30653940/)
[Zhang P, et al, Iron overload in Parkinson's disease: from ferroptosis to mitochondrial dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/36062176/)
[Stockwell BR, et al, Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease (2017)](https://doi.org/10.1016/j.cell.2017.09.021)
[Dexter DT, et al, The effect of systemic iron deficiency on dopaminergic neuron function: implications for Parkinson's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1826400/)
[Wang JY, et al, Iron accumulation in the substantia nigra of patients with Parkinson's disease: a 10-year follow-up study (2021)](https://pubmed.ncbi.nlm.nih.gov/34597952/)
[Devos D, et al, Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARK-II trial (2018)](https://pubmed.ncbi.nlm.nih.gov/29526356/)
[Guldberg HC, et al, Deferasirox (Exjade) crosses the blood-brain barrier and reduces brain iron in a mouse model (2013)](https://pubmed.ncbi.nlm.nih.gov/23295857/)
[Devos D, et al, Deferiprone in symptomatic Parkinsonian syndromes: a pragmatic, randomized, double-blind trial (2022)](https://pubmed.ncbi.nlm.nih.gov/35796012/)
[Weinreb O, et al, Novel iron chelator for Parkinson's disease: from bench to clinic (2013)](https://pubmed.ncbi.nlm.nih.gov/23543122/)
[Moreau C, et al, Brain iron depletion in PSP: a 12-month longitudinal MRI study (2022)](https://pubmed.ncbi.nlm.nih.gov/35046125/)
[Crapper McLachlan DR, et al, Aluminum and other metals in Alzheimer's disease (1988)](https://pubmed.ncbi.nlm.nih.gov/24263388/)
[Spindler M, et al, Coenzyme Q10 effects in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30718910/)